The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 68 results:
Author [ Title(Desc)] Type Year
Filters: Author is Sarafidis, Pantelis  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
R
Bakris, G., Sarafidis P., Agarwal, iv R., & Ruilope L. (2014).  Review of blood pressure control rates and outcomes.. J Am Soc Hypertens. 8(2), 127-41.
S
Dimitroulas, T., Sarafidis P., Roma V., Karagiannopoulou G., Kapoulas S., Dimitroula H., et al. (2010).  Scleroderma renal crisis accompanied by new-onset pulmonary arterial hypertension: an acute systemic endothelial injury? Case report and literature.. Inflamm Allergy Drug Targets. 9(4), 313-8.
Drosos, G., Ampatzidou F., Sarafidis P., Karaiskos T., Madesis A., & Boutou A. K. (2018).  Serum Creatinine and Chronic Kidney Disease-Epidemiology Estimated Glomerular Filtration Rate: Independent Predictors of Renal Replacement Therapy following Cardiac Surgery.. Am J Nephrol. 48(2), 108-117.
Sampani, E., Sarafidis P., Dimitriadis C., Kasimatis E., Daikidou D., Bantis K., et al. (2020).  Severe euglycemic diabetic ketoacidosis of multifactorial etiology in a type 2 diabetic patient treated with empagliflozin: case report and literature review.. BMC Nephrol. 21(1), 276.
Sarafidis, P., Ferro C. J., Morales E., Ortiz A., Malyszko J., Hojs R., et al. (2020).  SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.. Nephrol Dial Transplant. 35(10), 1825.
Sarafidis, P., Ferro C. J., Morales E., Ortiz A., Malyszko J., Hojs R., et al. (2019).  SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.. Nephrol Dial Transplant. 34(2), 208-230.
Piperidou, A., Loutradis C., & Sarafidis P. (2020).  SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives.. J Hum Hypertens.
Fernandez-Fernandez, B., Sarafidis P., Kanbay M., Navarro-González J. F., Soler M. José, Gorriz J. Luis, et al. (2020).  SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia.. Clin Kidney J. 13(5), 728-733.
Sarafidis, P., Loutradis C., Ferro C. J., & Ortiz A. (2020).  SGLT-2 Inhibitors to Treat Hyponatremia Associated with SIADH: A Novel Indication?. Am J Nephrol. 51(7), 553-555.
Tsioufis, C., Andrikou I., Pruijm M., Ponte B., Sarafidis P., Koureas A., et al. (2018).  Should renal color Doppler ultrasonography be a routine test in newly diagnosed hypertensive patient?. J Hypertens. 36(1), 16-22.
Sarafidis, P., & Papagianni A. (2019).  Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections.. Ann Intern Med. 171(12), 943-944.
Memmos, E., Sarafidis P., Pateinakis P., Tsiantoulas A., Faitatzidou D., Giamalis P., et al. (2019).  Soluble Klotho is associated with mortality and cardiovascular events in hemodialysis.. BMC Nephrol. 20(1), 217.
Malindretos, P., Sarafidis P., Lazaridis A., & Nikolaidis P. (2012).  A study of the association of higher parathormone levels with health-related quality of life in hemodialysis patients.. Clin Nephrol. 77(3), 196-203.
Saratzis, A., Sarafidis P., Melas N., Hunter J. P., Saratzis N., Kiskinis D., et al. (2012).  Suprarenal graft fixation in endovascular abdominal aortic aneurysm repair is associated with a decrease in renal function.. J Vasc Surg. 56(3), 594-600.
Zoccali, C., Vanholder R., Massy Z. A., Ortiz A., Sarafidis P., Dekker F. W., et al. (2017).  The systemic nature of CKD.. Nat Rev Nephrol. 13(6), 344-358.
T
Lampropoulou, I. Theologia, Stangou Μ., Sarafidis P., Gouliovaki A., Giamalis P., Tsouchnikas I., et al. (2020).  TNF-α pathway and T-cell immunity are activated early during the development of diabetic nephropathy in Type II Diabetes Mellitus.. Clin Immunol. 215, 108423.
Mallamaci, F., Torino C., Sarafidis P., Ekart R., Loutradis C., Siamopoulos K., et al. (2020).  Treatment-resistant hypertension in the hemodialysis population: a 44-h ambulatory blood pressure monitoring-based study.. J Hypertens. 38(9), 1849-1856.
Β
Demosthenous, C., Eleftheriou P., Apostolou C., Sarafidis P., Perifanis V., & Vlachaki E. (2018).  β-Thalassemia and renal complications. A narrative review of pathophysiologic mechanisms. Integrative Molecular Medicine. 5(4), 

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.